Article Sidebar

Submitted
September 8, 2020
Accepted
April 21, 2021
Published
July 19, 2021
Download
pdf
Statistic
Read Counter : 432 Download : 155

Downloads

Download data is not yet available.

Main Article Content

Abstract

The potency of stem cells in treatment or therapy is widely known due the properties of stem cells to differentiate into specialized cell type in the body. Application stem cells in medicine and therapy is mostly used for alternative treatment of diseases that could not be cured using chemical or other biological drugs, such as non-communicable diseases. In general, stem cells are classified in three types, namely Adult Stem Cells (ASC), Human Embryonic Stem Cells (hESC), and Induced Pluripotent Stem Cells. Each type of the cells has advantages and drawbacks for application in medicine and therapy. This review investigates whether iPS is the best approach for non-communicable disease treatment among other stem cell types.

Keywords

stem cells, non-communicable diseases, induced pluripotent stem cells

Article Details

How to Cite
Erwinda, Y. E. (2021). A Review: Induced Pluripotent Stem Cells (iPS) Therapy Is the Best Method to Cure Non-Communicable Diseases?. Eruditio : Indonesia Journal of Food and Drug Safety, 1(1), 11–18. https://doi.org/10.54384/eruditio.v1i1.29
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Hentze, H, Graichen, R & Colman, A 2006, ‘Cell therapy and the safety of embryonic stem cell-derived grafts’ ,Elsevier, vol. 25, no.1, pp. 24 – 33, viewed 2 February 2017, DOI: 10.1016/j.tibtech.2006.10.010.
  2. Higgs, DR 2008, ‘A new dawn for stem cell therapy’,The New England Journal of Medicine, vol. 358, no. 9, pp. 964 – 966, viewed 2 February 2017, DOI: 10.1056/NEJMcibr0708823
  3. Jarvis JD, Woods H, Bali A, Oronsaye E, Persaud N 2019, ‘Selection of WHO recommended essential medicines for non-communicable diseases on National Essential Medicines Lists’, PLoS ONE 14(8): e0220781. https://doi.org/10.1371/journal.pone.0220781
  4. Jones, E. A., Kinsey, S. E., English, A. 2002, ‘Isolation Characterization of Bone Marrow Potential Mesenchymal Progenitor Cells’, Arthritis and Rheumatism, vol. 46, no. 12, p. 3349 – 3360
  5. Jung, Y., Bauer, G., & Nolta, J. A. 2012, Concise Review: Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell: Progress Toward Safe Clinical Products, Stem Cells, 30(1), 42 – 47. doi:10.1002/stem.727
  6. Lo, B & Parham, L 2009, ‘Ethical issues in stem cell research’, Endocrine Reviews, vol. 30, no. 3, pp. 204-213, viewed 1 January 2017, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726839/?report=printable>.
  7. Kumar, AR, Kumar, SD & Nishanth, T 2012, ‘A review on stem cell research & their role in various diseases’, Journal Stem Cell Research & Therapy, vol. 1, viewed 20 December 2016, <https://www.omicsonline.org/a-review-on-stem-cell-research-their-role-in-various-diseases-2157-7633.1000112.pdf>.
  8. Mariano, ED, Teixeira, MJ, Marie, SKN & Lepski, G 2015, ‘Adult stem cells in neural repair: current options, limitations and perspectives’ ,World Journal of Stem Cells, 7(2), pp. 477 – 482, viewed 2 February 2016, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369503/pdf/WJSC-7-477.pdf>.
  9. Medvedev, SP, Shevchenko, AI & Zakian, SM 2010, ‘Induced pluripotent stem cells: Problems and advantages when applying them in regenerative medicine’, Acta Naturae Journal, vol 2, no.2 (5), viewed 21 December 2016, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347549/pdf/AN20758251-05-018.pdf>.
  10. Moon, SH, Kim, JS, Park, SJ, Lim, JJ, Lee, HJ, Lee, SM & Chung, HM 2011, ‘Effects of chromosome instability on the maintenance and differentiation of human embryonic stem cells in vitro and in vivo, ‘Elsevier, vol.6, pp. 50 – 59, viewed 2 February 2017, < http://ac.els-cdn.com/S187350611000098X/1-s2.0-S187350611000098X-main.pdf?_tid=07418abc-e921-11e6-98cf-00000aab0f6b&acdnat=1486024054_19bdff4c448e4692dd565eee8adf0207>.
  11. National Institute of Health 2016, Stem Cell Information, viewed 14 December 2016, <https://stemcells.nih.gov/info/basics/1.htm>.
  12. Parekkadan B., Milwid J.M. 2010, ‘Mesenchymal stem cells as therapeutics’, Annual Review Biomedical Engineering, vol. 12, p.87–117
  13. Pessôa, L. V. F., Bressan, F. F., Freude, K. K. 2019, Induced Pluripotent Stem Cells Throughout the Animal Kingdom: Availability and Applications, World Journal of Stem Cells, 11(8). P. 491 – 505. DOI: 10.4252/wjsc.v11.i8.491
  14. Rao, MS & Atala, A 2016, ‘Developing induced pluripotent stem cell-based therapy for the masses’ ,Stem Cells Translational Medicine, pp. 129 – 131, viewed 9 February 2016, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729557/>.
  15. Ruby A, Knight A, Perel P, Blanchet K, Roberts B (2015) The Effectiveness of Interventions for Non-Communicable Diseases in Humanitarian Crises: A Systematic Review. PLoS ONE 10(9): e0138303. doi:10.1371/journal.pone.0138303
  16. Shah, K., 2016. ‘Stem cell-based therapies for tumors in the brain: Are We There Yet? Neuro-Oncology 18(8), p. 1066 – 1078. doi:10.1093/neuonc/now096
  17. Song, JM & Bharti, K 2016, ‘Looking into the future: using induced pluripotent stem cells to build two and three dimensional ocular tissue for cell therapy and diseases modelling’,Elsevier, vol. 1638, pp. 2-14.
  18. Trounson, A & McDonald, C 2015, ‘Stem cell therapies in clinical trials:progress and challenges’, Cell Stem Cell, no.17, pp. 11-22, viewed 1 January 2017, <http://www.cell.com/cell-stem-cell/pdf/S1934-5909(15)00267-2.pdf>.
  19. Weissman, I. L. 2000’. Stem cells: units of development, units of regeneration, and units in evolution’, Cell, no. 100, 157–168. doi: 10.1016/S0092-8674(00)81692-X
  20. World Health Organization 2014, Global status report on non-communicable diseases 2014, viewed 18 December 2016, <http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf>.
  21. Yee, JK 2010, ‘Turning somatic cells into pluripotent stem cells’, Nature Education, vol. 3, no. 9, viewed 1 January 2017, <http://www.nature.com/scitable/topicpage/turning-somatic-cells-into-pluripotent-stem-cells-14431451>.